Valery Trancon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valery Trancon has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Gustavo Lorenzo Moretta
Universidad San Martín de Porres, Peru
2 shared publications - Jose Francisco Parodi
Universidad San Martín de Porres, Peru
2 shared publications - Ricardo Fujita
Universidad de San Martín de Porres, Peru
2 shared publications - Elder Vicente Quispe-Huamani
Hospital Nacional Edgardo Rebagliati Martins: Lima, Lima, PE, Peru
1 shared publication - Eliana Mateus
Universidad de Colombia, Colombia
1 shared publication - Fiorella Navarro-Vásquez
Hospital Nacional Dos de Mayo, Peru
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by MDPI AG in Preprints.org
Translational Pharmacoeconomics in Rare Diseases: Integrating Clinical, Economic, and Social Value in Health Decision-Making
Rare diseases pose a growing challenge for health systems due to the combination of high clinical need, limited evidence, and elevated costs. This article analyzes the intersection between translational medicine and pharmacoeconomics, identifying a structural gap between the clinical value of innovations and traditional economic evaluation frameworks. Drawing on a narrative review of the literature—in which 240 scientific articles were identified and the 30 most methodologically and thematically relevant were selected through systematic screening by title, abstract, and full-text relevance—and a comparative analysis of frameworks in Europe, the United States, and Latin America, we propose the concept of translational pharmacoeconomics as an integrative framework that explicitly incorporates clinical, economic, and social dimensions of value into health decision-making. This approach has direct implications for the design of more equitable, adaptive, and sustainable health policies, particularly in contexts of evidence scarcity and unmet clinical need.
- 30 April 2026
- Published by MDPI AG in Preprints.org
Open AccessTranslational Pharmacoeconomics in Rare Diseases: Integrating Clinical, Economic, and Social Value in Health Decision-Making
Rare diseases pose a growing challenge for health systems due to the combination of high clinical need, limited evidence, and elevated costs. This article analyzes the intersection between translational medicine and pharmacoeconomics, identifying a structural gap between the clinical value of innovations and traditional economic evaluation frameworks. Drawing on a narrative review of the literature—in which 240 scientific articles were identified and the 30 most methodologically and thematically relevant were selected through systematic screening by title, abstract, and full-text relevance—and a comparative analysis of frameworks in Europe, the United States, and Latin America, we propose the concept of translational pharmacoeconomics as an integrative framework that explicitly incorporates clinical, economic, and social dimensions of value into health decision-making. This approach has direct implications for the design of more equitable, adaptive, and sustainable health policies, particularly in contexts of evidence scarcity and unmet clinical need.
- Open Access
- 29 April 2026
- Published by MDPI AG in Preprints.org
Clinical, Genetic and Phenotypic Characterization of Hereditary Transthyretin Amyloidosis (ATTRv) in Peruvian Population: Real-World Data from a Case Series — IMPAC-FE Study
Background: Hereditary transthyretin amyloidosis (ATTRv) is a rare multisystemic disease with variable phenotypic expression. No published data exist on the clinical characteristics of ATTRv in Peruvian population.Objective: To describe the demographic, genetic, and clinical characteristics of patients with ATTRv in Peru, and to determine the distribution of clinical phenotypes according to internationally validated criteria.Methods: Descriptive, observational, retrospective case series of patients with ATTRv confirmed by molecular genetic testing, evaluated in Lima, Peru, between 2021 and December 2025 (IMPAC-FE study). Demographic, genetic, neurological (NIS, Norfolk QOL-DN, PND), autonomic (COMPASS-31, SUDOSCAN), and cardiovascular variables (echocardiography, septal thickness, E/e', apical sparing pattern, Tc99m-pyrophosphate scintigraphy, NT-proBNP, troponin) were evaluated. Phenotypes were classified according to AHA/ACC criteria and the THAOS registry.Results: Twenty-three patients were included (69.6% male, median age 60 years, IQR 45-70). The variants were Val142Ile (56.5%), Ala65Val (34.8%), and Val50Met (8.7%). Overall phenotype distribution: preclinical 34.8%, mixed 39.1%, cardiac 21.7%, neurological 4.3%. Norfolk QOL-DN (n=18): median 6.0. COMPASS-31 (n=18): median 6.0. LVEF (n=16): mean 60.5%. LV Mass (n=12): mean 102.9g. Troponin T (n=9): median 47 ng/L. PYP Scintigraphy (n=9): Perugini 3 in 77.8%.Conclusions: This first case series of ATTRv in Peruvian population shows clinical and genetic heterogeneity, with predominance of Val142Ile and Ala65Val variants, and a phenotypic distribution compatible with international registries. The high proportion of preclinical patients and extended cardiovascular evaluation reinforce the need for early diagnosis and timely initiation of disease-modifying therapies.
- 29 April 2026
- Published by MDPI AG in Preprints.org
Open AccessClinical, Genetic and Phenotypic Characterization of Hereditary Transthyretin Amyloidosis (ATTRv) in Peruvian Population: Real-World Data from a Case Series — IMPAC-FE Study
Background: Hereditary transthyretin amyloidosis (ATTRv) is a rare multisystemic disease with variable phenotypic expression. No published data exist on the clinical characteristics of ATTRv in Peruvian population.Objective: To describe the demographic, genetic, and clinical characteristics of patients with ATTRv in Peru, and to determine the distribution of clinical phenotypes according to internationally validated criteria.Methods: Descriptive, observational, retrospective case series of patients with ATTRv confirmed by molecular genetic testing, evaluated in Lima, Peru, between 2021 and December 2025 (IMPAC-FE study). Demographic, genetic, neurological (NIS, Norfolk QOL-DN, PND), autonomic (COMPASS-31, SUDOSCAN), and cardiovascular variables (echocardiography, septal thickness, E/e', apical sparing pattern, Tc99m-pyrophosphate scintigraphy, NT-proBNP, troponin) were evaluated. Phenotypes were classified according to AHA/ACC criteria and the THAOS registry.Results: Twenty-three patients were included (69.6% male, median age 60 years, IQR 45-70). The variants were Val142Ile (56.5%), Ala65Val (34.8%), and Val50Met (8.7%). Overall phenotype distribution: preclinical 34.8%, mixed 39.1%, cardiac 21.7%, neurological 4.3%. Norfolk QOL-DN (n=18): median 6.0. COMPASS-31 (n=18): median 6.0. LVEF (n=16): mean 60.5%. LV Mass (n=12): mean 102.9g. Troponin T (n=9): median 47 ng/L. PYP Scintigraphy (n=9): Perugini 3 in 77.8%.Conclusions: This first case series of ATTRv in Peruvian population shows clinical and genetic heterogeneity, with predominance of Val142Ile and Ala65Val variants, and a phenotypic distribution compatible with international registries. The high proportion of preclinical patients and extended cardiovascular evaluation reinforce the need for early diagnosis and timely initiation of disease-modifying therapies.